Wydanie specjalne czerwiec 2014
Leczenie wysiękowej postaci zwyrodnienia plamki związanego z wiekiem lekiem Eylea w aspekcie wyboru najkorzystniejszej terapii dla pacjenta leczonego w ośrodku prywatnym – opis trzech przypadków
Treatment of Exudative Age-related Macular Degeneration Using Eylea Concerning Selection of the Best Therapy for a Patient Treated in Private Medical Center – Report of Three Cases
Adam Cywiński, Daniela Ferda, Małgorzata Świgoń
Śląski Ośrodek Leczenia Chorób Oczu w Żorach
Kierownik: dr n. med. Adam Cywiński
Summary: Purpose: The aim of the paper is to present and discuss three cases of neovascular age-related macular degeneration.
Material and Methods: Eamples of treatment modifications of three patients who were qualified to the anti-VEGF therapy. Each of them was included to the study because of a difference which was observed during treatment. Their common feature was Eylea instead of the previously used, in two cases because of lack of effectiveness, in the third because of the safety reasons and comfort for the patient. Diagnostic process included medical interview, visual function and fluorescein angiography, optical coherence tomography, and coloured fundus photo. Treatment was changed based on the results of optical coherence tomography and coluoured eye fundus. We want to pay attention to such important element of good therapy as treatment continuity and need for treatment modification in case of lack of the treatment efficiency.
Results: Longer acting preparation such use such as Eylea not only caused visual function improvement but, additionally allowed to increase the intervals between visits. Changing preparation doesn’t require loading dose once again, so it does not increase treatment cost. Visual function deterioration was mainly observed in case when anti-VEGF treatment was stopped, in one patient because of cataract surgery procedure. The anti-VEGF therapy is not a contraindication for cataract surgery, but we should remember that patient requires systematic postoperative follow-up and, if necessary anti-VEGF therapy treatment implementation. In situation when current treatment fails we should consider changing it to another.
Conclusions: The Eylea as a medicine with the longest time of action should be a drug of choice for treatment continuation in anti-VEGF therapy, even when another drug was used in a loading dose. Using it in 2 monthly or 3 monthly repeated doses gives a big chance to mantain visual function of the eye on a stable good level.
Słowa kluczowe: Eylea, zwyrodnienie plamki związane z wiekiem (AMD), angiografia fluoresceinowa (FA), optyczna koherentna tomografia (OCT).
Keywords: Eylea, age-related macular degeneration (AMD), fluorescein angiography (FA), optical coherence tomography (OCT).